Drug intelligence / Profile preview

cyclophosphamide + fluorouracil

Development stage
Unknown
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Intravenous, Oral
01

Overview

This combination appears in several chemotherapy regimens used primarily for breast cancer treatment. The search results show that cyclophosphamide and fluorouracil are frequently used together, often with a third drug such as methotrexate (forming CMF), doxorubicin/Adriamycin (forming CAF/FAC), or epirubicin (forming FEC/CEF)[1][2][3][4]. ## Combination Details Cyclophosphamide and fluorouracil work together as a chemotherapy combination, with each drug attacking cancer cells through different mechanisms. Cyclophosphamide is an alkylating agent that stops cancer cells from reproducing, while fluorouracil (also known as 5-FU) is an antimetabolite that stops cells from making and repairing DNA, causing them to die when they try to divide[2][3]. This combination is typically administered intravenously, though in some regimens cyclophosphamide may be given orally as a daily pill[2]. The specific dosing schedule varies depending on the complete regimen being used and whether additional drugs are included. ## Clinical Use The cyclophosphamide + fluorouracil combination is primarily used in breast cancer treatment, particularly for localized breast cancers with a relatively high risk of recurrence. It has shown effectiveness for both node-negative disease (which hasn't traveled to lymph nodes) and node-positive disease (which has traveled to lymph nodes)[2]. Common side effects of regimens containing cyclophosphamide and fluorouracil include nausea, vomiting, diarrhea, mouth sores, hair loss, low blood counts, fatigue, menopausal symptoms, and increased risk of infection[3]. Rare but serious side effects may include increased risk of leukemia and heart problems. Patients receiving this combination should avoid pregnancy during treatment and should inform their healthcare providers about all medications they're taking, including vitamins, supplements, and over-the-counter medicines[2][3].

Other names
cyclophosphamide + 5-FU
02

Targets

DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on cyclophosphamide + fluorouracil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + fluorouracil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call